Yahoo Finance

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

– DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 – BOSTON, May 28, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a ...
Seeking Alpha

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- BOSTON--(BUSINESS WIRE)-- PepGen Inc. (PEPG), a clinical-stage biotechnology company advancing ...
Seeking Alpha

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data - ...
Nature

Ephedrine hydrochloride inhibits PGN-induced inflammatory responses by promoting IL-10 production and decreasing proinflammatory cytokine secretion via the PI3K/Akt/GSK3β pathway

Approaches for controlling inflammatory responses and reducing the mortality rate of septic patients remain clinically ineffective; new drugs need to be identified that can induce anti-inflammatory ...
The American Journal of Managed Care

FDA Pauses PepGen’s DMD Drug Trial in the US

The FDA placed a clinical hold on PGN-EDO51's phase 2 trial. PGN-EDO51 targets exon 51 skipping in the dystrophin gene, showing promising results in earlier trials. Ongoing studies outside the US, ...
Business Wire

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...